Summary of "Farmakovigilans dan Keamanan Obat di Indonesia || ZOOMERGENCY261"

Main Ideas and Concepts

Introduction to Pro Emergency and Health Sector Context
- Pro Emergency is a nationally and internationally certified training institution focused on emergency health services and competency development for medical personnel and the community across Indonesia.
- The COVID-19 pandemic accelerated the need for rapid adaptation and improvement in health services, including Pharmacovigilance (drug safety monitoring).
Pharmacovigilance (PV) in Indonesia: Definition and Importance
- Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any drug-related problems.
- It is a critical component for ensuring patient safety, especially in a populous country like Indonesia with a vast pharmaceutical market and diverse healthcare facilities.
Challenges in Indonesian Pharmacovigilance
- Despite existing regulations and systems, challenges remain in drug supervision, side effect data management, public and healthcare professional awareness, and reporting frequency.
- Indonesia’s PV system is centralized under the Indonesian Food and Drug Agency (BPOM), which acts as the national PV center coordinating reports and safety monitoring.
Legal and Regulatory Framework
- Presidential Regulation No. 80 of 2017 and BPOM regulations, including the latest Number 15 of 2022, govern drug and food supervision, including PV activities.
- The 2022 regulation expanded PV obligations beyond pharmaceutical industry to include health facilities and healthcare practitioners.
Pharmacovigilance System Structure and Process
- PV covers pre-market (clinical trials, drug registration) and post-market surveillance (monitoring adverse drug reactions in the general population).
- Clinical trials have limitations (small sample sizes, controlled conditions) that necessitate ongoing post-market PV to detect rare or long-term side effects.
- Reporting mechanisms include electronic systems (e.g., Meso.pom.go.id), email, postal forms (yellow forms), and direct communication with BPOM or pharmaceutical companies.
- Causality assessment tools such as the Naranjo scale and Liverpool algorithm are used to evaluate the likelihood that a drug caused an adverse reaction.
Role of Stakeholders
- Pharmacists, doctors, nurses, midwives, pharmaceutical companies, BPOM, healthcare facilities, and patients all have roles in detecting, reporting, and managing drug safety.
- Pharmaceutical companies are responsible for maintaining PV systems, reporting adverse events, and collaborating with BPOM and international bodies.
- Healthcare practitioners are encouraged to report suspected adverse drug reactions (ADRs) even if they are known or listed on labels.
- Patients’ reports and awareness are important but currently underutilized.
Pharmacovigilance in Pharmaceutical Industry
- Industry PV systems include organizational structures with dedicated PV units and responsible persons with appropriate training.
- Continuous monitoring, risk-benefit assessment, quality management, and compliance with regulatory inspections are mandatory.
- Industry reports adverse events from spontaneous reports, clinical trials, scientific literature, and global safety information.
- Data management and reporting must align with international standards (e.g., XML, E2B formats) to facilitate global data exchange (e.g., WHO Uppsala Monitoring Centre).
Pharmacovigilance in Health Facilities
- Health facilities (hospitals, clinics, community health centers) face challenges in ADR reporting due to lack of awareness, unclear procedures, and limited resources.
- Training and capacity building for healthcare professionals are essential to improve detection and reporting.
- Pharmacists play a key role in identifying, assessing, and reporting ADRs to improve patient safety and support clinical decision-making.
Types and Classification of Adverse Drug Reactions (ADRs)
- ADRs are classified by dose-relatedness (Type A: dose-dependent and predictable; Type B: bizarre, unpredictable, often allergic), timing (acute, delayed, withdrawal), and frequency (common, rare).
- Medication errors and drug interactions also contribute to ADRs and must be distinguished from intrinsic drug side effects.
Case Studies and Practical Insights
- Examples include thalidomide’s historical birth defects leading to the establishment of PV systems, drug withdrawals due to safety concerns (e.g., rofecoxib), and recent drug-specific ADRs (e.g., Semaglutide-induced gastroparesis).
- Emphasis on reporting all suspected ADRs, even if known or rare, to build robust national safety data.
Tools and Systems for Reporting and Assessment
- Electronic reporting platforms (Meso, yellow forms) facilitate easier and more comprehensive ADR reporting.
- Causality assessment algorithms (Naranjo, Liverpool, WHO) help standardize evaluation and improve confidence in reports.
- Regular